All In Biotech

Drug Trial Radar · NCT00199420

A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa

A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of 10, 20 and 40 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy.

Last checked: Nov 19, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 580 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

580

Actual

Start

Jul 2004

Primary completion

Nov 2005

Study completion Dec 2005

Sponsor

Lead sponsor
Kyowa Kirin, Inc.Industry
Sponsor type
Industry
First posted
Sep 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To establish the efficacy of 10, 20 and 40 mg/d dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.

Conditions

  • Parkinson's Disease

Interventions

  • Istradefylline (KW-6002)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To establish the efficacy of 10, 20 and 40 mg/d istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa/carbidopa.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Kyowa Pharmaceutical Inc.

    Princeton, New Jersey

  • Kyowa Pharmaceutical

    Princeton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.